NovaBridge Biosciences Doses First Patient in Pivotal Phase 2 Study for Lead Gastric Cancer Drug Givastomig
NBP has more than doubled off its 52-week low of $0.595.
Summary
NovaBridge Biosciences announced the dosing of the first patient in its global, randomized Phase 2 study for Givastomig, a bispecific antibody for first-line metastatic gastric cancer, marking a critical advancement for its lead oncology candidate.
Key Events · Product Development and Regulatory · NBP
-
Phase 2 Study Initiated for Givastomig
NovaBridge Biosciences has dosed the first patient in a global, randomized Phase 2 study evaluating Givastomig in combination with immunochemotherapy for first-line metastatic gastric cancer.
-
Builds on Strong Phase 1b Data
The Phase 2 study follows positive Phase 1b combination data, which demonstrated a 75% objective response rate (ORR) and a median progression-free survival (mPFS) of 16.9 months, positioning Givastomig as a potential best-in-class therapy.
-
Significant Market Opportunity
Givastomig targets a gastric cancer market projected to reach $12 billion by 2030, highlighting the substantial commercial potential of the drug.
-
Topline Results Expected in 2027
The company anticipates releasing topline results from the Phase 2 study in 2027, with updated Phase 1b dose expansion data expected in the second half of 2026.
Analysis · NBP · Life Sciences
NovaBridge Biosciences has initiated a global Phase 2 study for Givastomig, its lead bispecific antibody targeting metastatic gastric cancer. This milestone is highly significant as it moves the company's most promising asset into a pivotal stage of clinical development, building on previously reported robust Phase 1b efficacy data. The drug is positioned as a potential best-in-class therapy for a gastric cancer market projected to reach $12 billion by 2030, underscoring its substantial commercial potential. Successful progression in this study could significantly de-risk the asset and drive future valuation.
At the time of this filing, NBP was trading at $3.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $370.1M. The 52-week trading range was $0.60 to $6.79. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.